Analysts’ Recent Ratings Updates for Rocket Pharmaceuticals (RCKT)

Several brokerages have updated their recommendations and price targets on shares of Rocket Pharmaceuticals (NASDAQ: RCKT) in the last few weeks:

• 8/17/2026 – Rocket Pharmaceuticals was upgraded by Wall Street Zen from “sell” to “hold”.
• 8/11/2026 – Rocket Pharmaceuticals was downgraded by Weiss Ratings from “sell (d-)” to “sell (e+)”.
• 8/11/2026 – Rocket Pharmaceuticals had its price target lowered by Wedbush from $16.00 to $15.00. They now have an “outperform” rating on the stock.
• 8/9/2026 – Rocket Pharmaceuticals was downgraded by Wall Street Zen from “hold” to “sell”.
• 8/1/2026 – Rocket Pharmaceuticals was upgraded by Wall Street Zen from “sell” to “hold”.
• 7/18/2026 – Rocket Pharmaceuticals was downgraded by Wall Street Zen from “hold” to “sell”.
• 7/15/2026 – Rocket Pharmaceuticals was upgraded by Weiss Ratings from “sell (e+)” to “sell (d-)”.
• 6/29/2026 – Rocket Pharmaceuticals was downgraded by Weiss Ratings from “sell (d-)” to “sell (e+)”.

Insider Activity at Rocket Pharmaceuticals

In related news, CEO Gaurav Shah sold 55,684 shares of the company’s stock in a transaction on Thursday, May 21st. The shares were sold at an average price of $3.09, for a total value of $172,063.56. Following the completion of the transaction, the chief executive officer directly owned 1,061,724 shares of the company’s stock, valued at approximately $3,280,727.16. This represents a 4.98% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, COO Christopher James Stevens sold 36,658 shares of the stock in a transaction dated Tuesday, August 11th. The stock was sold at an average price of $3.50, for a total value of $128,303.00. Following the transaction, the chief operating officer owned 505,784 shares of the company’s stock, valued at approximately $1,770,244. The trade was a 6.76% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold 103,373 shares of company stock valued at $338,215 in the last quarter. Corporate insiders own 21.30% of the company’s stock.

Rocket Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on developing gene therapies for rare, inherited pediatric diseases. The company employs a proprietary adeno-associated virus (AAV) and lentiviral vector platform to deliver functional copies of genes in patients with genetic deficiencies. Its programs target a spectrum of disorders, including Fanconi anemia, leukocyte adhesion deficiency type I and Danon disease, with the goal of delivering one-time treatments that address the underlying causes of disease rather than merely managing symptoms.

The company’s pipeline comprises multiple product candidates in various stages of development.